AtaiBeckley Inc. 8-K

What Happened
AtaiBeckley Inc. announced on March 6, 2026 that it entered into an Open Market Sale AgreementSM with Jefferies LLC to act as sales agent for an “at‑the‑market” equity offering program. Under the Sales Agreement the Company may, from time to time, issue and sell its common stock (par value $0.01) pursuant to its registration statement on Form S‑3 (File No. 333‑294124) and a prospectus supplement filed March 9, 2026. The Company also terminated its prior Open Market Sale Agreement with Jefferies dated November 10, 2022.

Key Details

• Sales Agreement date: March 6, 2026; prior agreement (Nov. 10, 2022) was terminated the same day.
• Jefferies will act as sales agent and will use commercially reasonable efforts to sell shares in “at‑the‑market” transactions.
• Commission: up to 3.0% of gross sales proceeds on shares sold through Jefferies.
• Company controls terms: it sets timing, number of shares, daily limits, minimum sale price and can suspend or instruct Jefferies not to sell. Proceeds intended for clinical development, working capital and general corporate purposes.

Why It Matters
This agreement gives AtaiBeckley a flexible, on‑demand way to raise capital by selling shares into the market when conditions are favorable. For investors, it means potential future dilution if shares are issued and sold, but also a ready mechanism for the company to fund clinical programs and operations without negotiating a fixed private placement. The 3.0% sales commission and the Company’s control over sale parameters are typical for such programs.